This meeting took place in 2015


Here are the related meetings in 2016:
HIV Persistence: Pathogenesis and Eradication (X7)

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Mechanisms of HIV Persistence: Implications for a Cure (E1)


Organizer(s) Olivier Lambotte, Steven G. Deeks and Guido Silvestri
April 26—May 1, 2015
Boston Park Plaza • Boston, Massachusetts USA
Discounted Abstract Deadline: Dec 22, 2014
Abstract Deadline: Jan 28, 2015
Scholarship Deadline: Dec 22, 2014
Discounted Registration Deadline: Feb 26, 2015

Sponsored by Bristol-Myers Squibb Company, Gilead Sciences, Inc., Merck & Co., Inc. and Sangamo BioSciences, Inc. Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation.

Summary of Meeting:
Despite long-term control of HIV replication with cART, HIV persists as silenced integrated DNA in memory CD4 T cells, and possibly in other cellular reservoirs, including naïve cells and macrophages. Low-level replenishment of the reservoir via limited cycles of replication may also contribute to persistence, at least in some patients. Curing HIV infection will only occur if these barriers are reversed, or if host capacity to control HIV indefinitely is improved. A number of promising interventions which might reverse latent infection have been identified, and proof that such drugs affect HIV transcription in vivo provided in pilot clinical trials. The observation that few patients treated during primary infection durably control replication-competent HIV after interrupting therapy suggests host responses might be manipulated, leading to a functional cure. The path forward will require a detailed understanding of the mechanisms of viral latency which could lead to the identification of new drugs, and a better knowledge of the plasticity and dynamics of the main HIV cell reservoirs: CD4 T cells and macrophages. The role of the tissue microenvironment has to be underlined with the major help of non-human primate models. At this meeting, experts from both within and outside the HIV field will present findings from recent advances on immune mechanisms and therapeutic strategies which could lead to an HIV cure.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


SUNDAY, APRIL 26

16:00—20:00
Arrival and Registration

18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.


MONDAY, APRIL 27

07:30—08:30
Breakfast

08:00—08:30
Poster Setup

08:30—17:00
Poster Viewing

08:30—09:30
Keynote Address
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Olivier Lambotte, University Paris South, France

* Guido Silvestri, Emory University School of Medicine, USA

* Steven G. Deeks, University of California, San Francisco, USA

Francoise Barré-Sinoussi, Institut Pasteur, France
HIV Cure as an Aspirational Goal

09:30—11:45
Biology of HIV Latency
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

Monsef Benkirane, Institut de Genetique Humaine, France
Toward Development of an Animal Model Dedicated to Explore HIV-1 Persistence

* Carine Michele Van Lint, University of Brussels, Belgium
Molecular Mechanisms of HIV-1 Postintegration Latency: Implications for Therapeutic Strategies

Lillian B. Cohn, Rockefeller University, USA
Short Talk: HIV-1 Integration Landscape in Active and Latent Infection

Kai Deng, Johns Hopkins Medical Institutes, USA
Short Talk: The Establishment of HIV-1 Latency Is Restricted within a Small Subset of Primary CD4+ T Cells and Can Be Prevented by Viral-Specific CTLs

Valentina Vongrad, University Hospital Zürich, Switzerland
Short Talk: Longitudinal Patterns of HIV-1 Integration Sites (IS) in CD4+ T Cell Subsets in vivo

10:10—10:40
Coffee Break

11:45—12:45
Lunch

12:15—14:30
Poster Session 1

14:30—16:30
Workshop 1: HIV Reservoirs, Clinical Care and Clinical Results

* Christine Rouzioux, Necker Hospital and University of Paris Descartes, France
HIV Reservoirs Measurement in Clinical Care: Where Are We Going?

Katherine M. Bruner, Johns Hopkins University School of Medicine, USA
Analysis of HIV-1 Genomes in the Latent Reservoir Indicates Rapid Accumulation of Defective Proviruses

Rémi Fromentin, , Canada
Distribution of Cellular HIV Reservoirs after more than 15 Years of ART

Alexander O. Pasternak, Academic Medical Center of the University of Amsterdam, Netherlands
Long-Term Effect of Temporary ART during Primary HIV Infection on the Viral Reservoir

Miles P. Davenport, University of New South Wales, Australia
Low Frequency of HIV Rebound after Antiretroviral Treatment Interruption

16:30—17:00
Coffee Available

17:00—19:15
Detection and Quantification of HIV Reservoirs
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

Ronald N. Germain, NIAID, National Institutes of Health, USA
Imaging Immunity: Creating a Spatiotemporal Understanding of Host Defense

* Robert F. Siliciano, Johns Hopkins University School of Medicine, USA
HIV Reservoirs: What We Know and What We Don't Know

Una O'Doherty, University of Pennsylvania Medical Center, USA
HIV Reservoir Expression

Douglas D. Richman, University of California, San Diego, USA
Measuring the Latent Reservoir

19:15—
On Own for Dinner


TUESDAY, APRIL 28

07:30—08:30
Breakfast

08:30—11:45
CD4 T Cells as Reservoir
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

Chen Dong, Tsinghua University, China
T Cell Subsets in Immunity

* Sharon R. Lewin, University of Melbourne, Australia
Chemokines and the HIV Reservoir in CD4 T Cells

Richard A. Koup, NIAID, National Institutes of Health, USA
Tfh Cells Are a Site of Active HIV Replication

Matthieu Perreau, University Hospital of Lausanne, Switzerland
Short Talk: Lymph node PD-1+/Tfh Memory CD4 T Cells Are the Major Source of HIV-1 Replication Competent and Infectious Virus in Long-Term Treated Aviremic HIV-Infected Subjects

Joseph K. Wong, University of California, San Francisco, USA
Charateristics of Tissue HIV Reservoirs in vivo

Eli Boritz, NIAID, National Institutes of Health, USA
Short Talk: Mechanisms of HIV Persistence in HIV Controllers

09:50—10:10
Coffee Break

11:45—13:00
Poster Setup

13:00—22:00
Poster Viewing

11:45—17:00
On Own for Lunch

14:30—16:30
Workshop 2: Modulations of the Immune System to Reduce the Size of HIV Reservoirs

* Asier Sáez-Cirión, Institut Pasteur, France

Zelda Euler, Ragon Institute of MGH, MIT and Harvard, USA
Eradication of HIV Reservoirs with Antibody-Mediated Killing

Edward A. Berger, NIAID, National Institutes of Health, USA
Targeted Cell Killing to Achieve a (Functional) Cure: Different Strategies for Acute Versus Chronic Infection

Selena Viganò, Ragon Institute, USA
Immune Correlates of HIV-1 DNA Decrease during Treatment with Pegylated IFN-alpha in HIV/HCV Co-Infected Patients

Emily R. Roberts, University of Pennsylvania, USA
Rapid Evolution of SIV-Specific CD8 T Cell Cytolytic Potential during Acute SIV Infection

Kellie N. Smith, Johns Hopkins University School of Medicine, USA
Effective Targeting of the HIV Reservoir Requires a Broad de novo Induction of Primary Rather than Memory CTL

Guido Silvestri, Emory University School of Medicine, USA
Anti-Apoptosis Agent Preserves CD4 T Cells and Prevents Disease Progression in SIV-Infected Rhesus macaques

George B. Kyei, Washington University, USA
Largazoles Are a Novel Group of Lysine Deacetylase Inhibitors that Potently Reactivate HIV from Latency

Petronela Ancuta, Centre de Recherche de l'Universite de Montreal, Canada
Persistence of Replication Competent HIV-1 Reservoirs under ART in Central Memory Th17 Cells

16:30—17:00
Coffee Available

17:00—19:00
Non-CD4 T Cell Reservoirs
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

Jason M. Brenchley, NIAID, National Institutes of Health, USA
Phagocytosis of SIV-Infected T Cells Can Explain Viral DNA within Myeloid Cells in vivo

* Olivier Lambotte, University Paris South, France
Adipose Tissue Is a Neglected Viral Reservoir and an Inflammatory Site during Chronic HIV and SIV Infection

Melissa J. Churchill, Burnet Institute for Medical Research, Australia
Microglia and the CNS as a Sanctuary for HIV

Serge Benichou, Cochin Institute, France
Short Talk: Productive HIV-1 Infection of Macrophages by Viral Cell-to-Cell Transfer from Infected CD4+ T Lymphocytes

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

19:30—22:00
Poster Session 2


WEDNESDAY, APRIL 29

07:30—08:30
Breakfast

08:30—11:45
Functional Eradication of HIV Reservoirs: Current Approaches and New Directions
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Steven G. Deeks, University of California, San Francisco, USA
Short-Term Disulfiram to Reverse Latent HIV Infection

Thomas A. Rasmussen, Aarhus University Hospital, Denmark
Reversal of HIV-1 Latency by HDAC Inhibitors: Part of a Curative Strategy?

Paula M. Cannon, University of Southern California, Keck School of Medicine, USA
Targeted Nuclease Approaches for a Functional Cure

Romas Geleziunas, Gilead Sciences, Inc., USA
Concepts of Combination Therapy to Achieve ART-Free HIV Remission

R. Brad Jones, Ragon Institute of MGH, MIT and Harvard, USA
Short Talk: Cytotoxic T-Lymphocytes in Combination with the IL-15 Superagonist ALT-803 Eliminate Latently HIV-Infected Autologous CD4+ T-Cells from Natural Reservoirs

Joumana Zeidan, Case Western Reserve University, USA
Short Talk: Decay of the HIV Reservoir Post Autologous Transfer of ZFN CCR5 Modified CD4 T Cells (SB-728-T) Correlates with Generation of a T Memory Stem Cell-Like Population and Enhanced HIV-Specific CD8 T Cell Polyfunctionality

09:50—10:10
Coffee Break

11:45—13:00
Poster Setup

13:00—22:00
Poster Viewing

11:45—17:00
On Own for Lunch

13:30—16:30
NeuroHIV Workshop Program:HIV Persistence in the CNS: Controversies and Challenges
Organizers: Serena Spudich, Victor Valcour, Jeymohan Joseph and Jintanat Ananworanich

13:30—14:40
NeuroHIV Workshop Program: Investigating HIV Persistence in the CNS
Organized by the National Institute of Mental Health (NIMH) Coordinated by the International NeuroHIV Cure Consortium (INHCC) (www.inhcc.net)

* Victor Valcour, University of California, San Francisco, USA

* Jeymohan Joseph, NIMH, National Institutes of Health, USA
Opening Remarks

Janice E. Clements, Johns Hopkins University, USA
HIV CURE: Reactivation of SIV in Plasma, CSF and CNS in the SIV Macaque Model

Sandhya Vasan, US Military HIV Research Program, USA
CNS Findings in a Non-Accelerated SHIV Macaque Model

Sarah E. Palmer, Westmead Millennium Institute for Medical Research, Australia
Low Level CSF HIV Persistence during Systemic Antiretroviral Suppression

Richard W. Price, University of California, San Francisco, USA
Persistent CNS Immune Activation in Treated HIV

Serena Spudich, Yale University, USA
Early Detection of HIV in the CNS and Impact of Early Treatment

14:50—16:20
NeuroHIV Workshop Program: State of the Science Discussion Panels A and B
Organized by National Institute of Mental Health (NIMH) Coordinated by the International NeuroHIV Cure Consortium (INHCC) (www.inhcc.net)

14:50—15:40
Panel A: Are Myeloid Cells Infected by HIV?

* Steven G. Deeks, University of California, San Francisco, USA

Lishomwa C. Ndhlovu, University of Hawaii, USA

Jason M. Brenchley, NIAID, National Institutes of Health, USA

Mario Stevenson, University of Miami, Leonard M. Miller School of Medicine, USA

J. Victor Garcia-Martinez, University of North Carolina at Chapel Hill, USA

Karl Salzwedel, NIAID, National Institutes of Health, USA

15:40—16:20
Panel B: Is the CNS a Potential Reservoir for HIV?

* Jintanat Ananworanich, US Military HIV Research Program, USA

Melissa J. Churchill, Burnet Institute for Medical Research, Australia

Douglas D. Richman, University of California, San Diego, USA

Ronald I. Swanstrom, University of North Carolina at Chapel Hill, USA

David M. Margolis, University of North Carolina at Chapel Hill, USA

16:30—17:00
Coffee Available

17:00—19:00
How to Fight Immune Exhaustion?
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

Daniel E. Kaufmann, University of Montreal, Canada
Co-Inhibitory Pathways and HIV Persistence

Stephen Mason, Bristol-Myers Squibb, USA
Approaches to HIV Remission

* Rafick-Pierre Sékaly, Case Western Reserve University, USA
Promoting CD4 Differentiation

Colleen S. McGary, Emory University, USA
Short Talk: CTLA-4-Expressing CD4 T Cells Are Critical Contributors to SIV Viral Persistence

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

19:30—22:00
Poster Session 3


THURSDAY, APRIL 30

07:30—08:30
Breakfast

08:30—12:00
Strengths and Weaknesses of NHP Models
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Guido Silvestri, Emory University School of Medicine, USA
Optimizing the NHP Model for Cure Studies

Caroline P.B. Passaes, Institut Pasteur, France
Animal Models of Spontaneous Control: Lessons Learned and Future Directions

Gregory Q. Del Prete, Leidos Biomedical Research, Inc., Frederick National Lab, USA
Development and Utilization of Non-Human Primate Models of Combination Antiretroviral Therapy for Studies of HIV Functional Cure/Eradication

Afam Okoye, Oregon Health & Science University, USA
Early Antiretroviral Therapy Limits Viral Reservoir in SIV-Infected Macaques

Pamela J. Skinner, University of Minnesota, USA
Short Talk: Location, Abundance and Phenotype of Follicular SIV-Specific CTL during Chronic Infection

Emily Ryan, Emory University, USA
Short Talk: Loss of Function of Intestinal Th17 and Th22 Cells Contributes to Persistent Immune Activation in SIV-Infected Rhesus macaques

Khader Ghneim, Case Western Reserve University, USA
Short Talk: FOXO3 and the Interferon Pathway Regulate Immune Reconstitution and the Size of the HIV Reservoir

09:50—10:10
Coffee Break

12:00—17:00
On Own for Lunch

14:30—16:30
Workshop 4: Strategies to Reduce HIV Reservoirs: The Point of View of the Patient

* Olivier Lambotte, University Paris South, France
Perspectives on the Acceptability of HIV Cure Trials: The Challenges for Physicians and PLWHIV (ANRS APSEC)

Sara Morón-López, AIDS Research Institute - IrsiCaixa, Spain
Impact of IFNalpha-2a on the Replication-Competent HIV-1 Reservoir in CD4+ T Cells

Genevieve Clutton, University of North Carolina, USA
Differential Effects of HIV Latency Reversing Agents on T Cell Phenotype and Function: Implications for HIV Cure

Miguel de Mulder Rougvie, George Washington University, USA
Modulation of HERV Family Expression after Treatment with HDAC Inhibitors

Sulggi Angela Lee, University of California, San Francisco, USA
Anti-HIV Antibody Responses Reflect the Quantifiable HIV Reservoir Size

Johanna Tauriainen, Karolinska Institutet, Sweden
Sustained Expression of the Inhibitory Receptor TIGIT Is Linked to CD8 T Cell Exhaustion Despite Successful ART

16:30—17:00
Coffee Available

17:00—18:45
Limitations of Antiretroviral Therapy and New Perspectives
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Courtney Fletcher, University of Nebraska Medical Center, USA
Is There a Pharmacologic Basis for Persistent HIV Replication?

Asier Sáez-Cirión, Institut Pasteur, France
Treat Early Is the Clue? Example of the Post-Treatment Controllers

Jintanat Ananworanich, US Military HIV Research Program, USA
Effects of Treatment during Acute HIV Infection on HIV Persistence

18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.


FRIDAY, MAY 1

 
Departure


*Session Chair †Invited, not yet responded.

Registered Attendees

Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online before the meeting...these abstracts will be available in the Abstract Book at the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

Boston Park Plaza Floorplan




Keystone Symposia thanks our Sponsors for generously supporting this meeting:

Bill & Melinda Gates Foundation Bristol-Myers Squibb Company
Gilead Sciences, Inc. Merck & Co., Inc.
Sangamo BioSciences, Inc.
 

We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13AI116250-01

The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.


We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Gilead Sciences, Inc.


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Assistant Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676